Trials / Recruiting
RecruitingNCT05456100
Chinese American Cancer Survivors Writing Study
A Randomized Controlled Trial Testing Expressive Helping for Chinese American Cancer Survivors
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- Sponsor
- New York University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The Chinese American Cancer Survivors Writing Study is a Randomized Controlled Trial (RCT) testing the feasibility and efficacy of the Expressive Helping (EH) intervention among Chinese American cancer survivors.
Detailed description
Chinese Americans are one of the fastest growing immigrant groups in the United States, but there is still a lack of culturally-sensitive and linguistically-appropriate resources and interventions for this group. To address this gap, the investigators will examine the efficacy and feasibility of Expressive Helping, a writing intervention designed to lead participants to write about their cancer experiences. Participants will be adult cancer survivors of Chinese descent. After screening and consent, eligible participants will be enrolled in a 1:1:1 randomized controlled trial. Assessments of psychological symptoms will occur at baseline (prior to randomization), 1-month post-intervention, 3-months post-intervention, and 6-months post-intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Expressive Helping | Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks. |
| BEHAVIORAL | Expressive Writing | Expressive writing involves emotional disclosure writing over four weeks. |
| BEHAVIORAL | Factual Writing | Factual writing involves writing facts about cancer treatment and experiences over four weeks. |
Timeline
- Start date
- 2022-07-14
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
- First posted
- 2022-07-13
- Last updated
- 2025-12-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05456100. Inclusion in this directory is not an endorsement.